ReviewCNS drugs2026
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
Review in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cannabigerol at the Interface of the Gut Microbiota and EndoCannabinoidome: Mechanistic Insights into Inflammation and Pain Modulation.Medical sciences (Basel, Switzerland) · 2026Review
- Molecular target for neuroinflammation and pain management: transient receptor potential vanilloid 1.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capsaicin has proven itself to be a valuable addition to the pain therapeutic toolbox, but the development of other transient receptor potential vanilloid 1 (TRPV1)-targeted agents has been slow. As a multi-functional channel involved with various signaling pathways, TRPV1 has been challenging to target therapeutically while minimizing side effects. In addition to nociception, TRPV1 responds to temperature to aid thermoregulation and signals chemical responses to noxious environmental stimuli. There is still continued research and evolving structural understanding of the receptor given its complexity and integral function within the body's overall self-regulation. Both agonist and antagonist approaches are being actively explored to help treat patients with neuropathic and musculoskeletal pain. Promising pharmaceutical agonists for pain include low- and high-dose capsaicin formulations, resiniferatoxin, CNTX-4975, and vocacapsaicin. Potentially applicable antagonist drugs include NEO6860, Mavatrep, ACD-440, AJH-2947, DWP05195, and XEN-DO501. As our understanding of TRPV1 channels has continued to increase since the initial discovery, we are at last beginning to see some positive clinical developments for TRPV1 drugs in the realm of neuropathic, post-operative, musculoskeletal, and cancer pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.